2026 ICD-10-CM Diagnosis Code Z16.20Resistance to unspecified antibiotic
Z16.20 is a billable ICD-10-CM diagnosis code for resistance to unspecified antibiotic. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 867 through 869. The code is not accepted as a principal diagnosis by the Medicare Code Editor. Coders also document this condition as antibiotic resistant tuberculosis. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Resistance to antimicrobial drugs.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for Z16.20.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Antibiotic resistant tuberculosis
- Drug resistance
- Drug resistance to antibacterial agent
- Infection caused by extended spectrum beta-lactamase producing bacteria
- Therapy failure due to antibiotic resistance
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Resistance to antibiotics NOS
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- to
- antibiotic (s) - Z16.20
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Resistance, resistant(to)
- organism (s)
- to
- drug
- antibiotic (s)
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Drug Resistance
diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. it should be differentiated from drug tolerance which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.Drug Resistance, Bacterial
the ability of bacteria to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. this resistance may be acquired through gene mutation or foreign dna in transmissible plasmids (r factors).Drug Resistance, Fungal
the ability of fungi to resist or to become tolerant to chemotherapeutic agents, antifungal agents, or antibiotics. this resistance may be acquired through gene mutation.Drug Resistance, Microbial
the ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. this resistance may be acquired through gene mutation or foreign dna in transmissible plasmids (r factors).Drug Resistance, Multiple
simultaneous resistance to several structurally and functionally distinct drugs.Drug Resistance, Multiple, Bacterial
the ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. this resistance may be acquired through gene mutation or foreign dna in transmissible plasmids (r factors).Drug Resistance, Multiple, Fungal
the ability of fungi to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. this resistance phenotype may be attributed to multiple gene mutations.Drug Resistance, Multiple, Viral
the ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. this resistance phenotype may be attributed to multiple gene mutation.Drug Resistance, Neoplasm
resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Drug Resistance, Viral
the ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. this resistance is acquired through gene mutation.Drug Tolerance
progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. it should be differentiated from drug resistance wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. it should also be differentiated from maximum tolerated dose and no-observed-adverse-effect level.
Convert Z16.20 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About Z16.20Overview
Is Z16.20 (Resistance to other antibiotics) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report resistance to unspecified antibiotic on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does Z16.20 group to?
On inpatient claims, resistance to unspecified antibiotic maps to MS-DRG 867, 868, 869, with relative weights from 0.7297 to 2.0932 depending on complications. Higher weights mean higher Medicare reimbursement.
Can Z16.20 be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because resistance to unspecified antibiotic describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
What is the ICD-9 equivalent of Z16.20?
Under the General Equivalence Mappings, resistance to unspecified antibiotic converts to ICD-9-CM V09.80 (inf mcr rst ot drg nt ml). The mapping is approximate, so confirm the match fits the documentation.
